Anthony Bates1,2, Kenneth Miles3,4. 1. Princess Alexandra Hospital, Brisbane, QLD, Australia. anthony.bates@uqconnect.edu.au. 2. , 21 Kipling St, Moorooka, QLD, 4105, Australia. anthony.bates@uqconnect.edu.au. 3. Department of Diagnostic Radiology, Princess Alexandra Hospital, Brisbane, QLD, Australia. 4. Institute of Nuclear Medicine, University College London, London, UK.
Abstract
OBJECTIVES: To validate MR textural analysis (MRTA) for detection of transition zone (TZ) prostate cancer through comparison with co-registered prostate-specific membrane antigen (PSMA) PET-MR. METHODS: Retrospective analysis was performed for 30 men who underwent simultaneous PSMA PET-MR imaging for staging of prostate cancer. Thirty texture features were derived from each manually contoured T2-weighted, transaxial, prostatic TZ using texture analysis software that applies a spatial band-pass filter and quantifies texture through histogram analysis. Texture features of the TZ were compared to PSMA expression on the corresponding PET images. The Benjamini-Hochberg correction controlled the false discovery rate at <5%. RESULTS: Eighty-eight T2-weighted images in 18 patients demonstrated abnormal PSMA expression within the TZ on PET-MR. 123 images were PSMA negative. Based on the corrected p-value of 0.005, significant differences between PSMA positive and negative slices were found for 16 texture parameters: Standard deviation and mean of positive pixels for all spatial filters (p = <0.0001 for both at all spatial scaling factor (SSF) values) and mean intensity following filtration for SSF 3-6 mm (p = 0.0002-0.0018). CONCLUSION: Abnormal expression of PSMA within the TZ is associated with altered texture on T2-weighted MR, providing validation of MRTA for the detection of TZ prostate cancer. KEY POINTS: • Prostate transition zone (TZ) MR texture analysis may assist in prostate cancer detection. • Abnormal transition zone PSMA expression correlates with altered texture on T2-weighted MR. • TZ with abnormal PSMA expression demonstrates significantly reduced MI, SD and MPP.
OBJECTIVES: To validate MR textural analysis (MRTA) for detection of transition zone (TZ) prostate cancer through comparison with co-registered prostate-specific membrane antigen (PSMA) PET-MR. METHODS: Retrospective analysis was performed for 30 men who underwent simultaneous PSMA PET-MR imaging for staging of prostate cancer. Thirty texture features were derived from each manually contoured T2-weighted, transaxial, prostatic TZ using texture analysis software that applies a spatial band-pass filter and quantifies texture through histogram analysis. Texture features of the TZ were compared to PSMA expression on the corresponding PET images. The Benjamini-Hochberg correction controlled the false discovery rate at <5%. RESULTS: Eighty-eight T2-weighted images in 18 patients demonstrated abnormal PSMA expression within the TZ on PET-MR. 123 images were PSMA negative. Based on the corrected p-value of 0.005, significant differences between PSMA positive and negative slices were found for 16 texture parameters: Standard deviation and mean of positive pixels for all spatial filters (p = <0.0001 for both at all spatial scaling factor (SSF) values) and mean intensity following filtration for SSF 3-6 mm (p = 0.0002-0.0018). CONCLUSION: Abnormal expression of PSMA within the TZ is associated with altered texture on T2-weighted MR, providing validation of MRTA for the detection of TZ prostate cancer. KEY POINTS: • Prostate transition zone (TZ) MR texture analysis may assist in prostate cancer detection. • Abnormal transition zone PSMA expression correlates with altered texture on T2-weighted MR. • TZ with abnormal PSMA expression demonstrates significantly reduced MI, SD and MPP.
Entities:
Keywords:
Cancer; Diagnosis; Magnetic resonance imaging; Prostate; Texture analysis
Authors: Caroline M A Hoeks; Thomas Hambrock; Derya Yakar; Christina A Hulsbergen-van de Kaa; Ton Feuth; J Alfred Witjes; Jurgen J Fütterer; Jelle O Barentsz Journal: Radiology Date: 2012-11-09 Impact factor: 11.105
Authors: Harbir S Sidhu; Salvatore Benigno; Balaji Ganeshan; Nikos Dikaios; Edward W Johnston; Clare Allen; Alex Kirkham; Ashley M Groves; Hashim U Ahmed; Mark Emberton; Stuart A Taylor; Steve Halligan; Shonit Punwani Journal: Eur Radiol Date: 2016-09-12 Impact factor: 5.315
Authors: Christian J Konopka; Marcin Woźniak; Jamila Hedhli; Anna Siekierzycka; Jarosław Skokowski; Rafał Pęksa; Marcin Matuszewski; Gnanasekar Munirathinam; Andre Kajdacsy-Balla; Iwona T Dobrucki; Leszek Kalinowski; Lawrence W Dobrucki Journal: Eur J Nucl Med Mol Imaging Date: 2020-03-12 Impact factor: 9.236
Authors: Katja Pinker; Fuki Shitano; Evis Sala; Richard K Do; Robert J Young; Andreas G Wibmer; Hedvig Hricak; Elizabeth J Sutton; Elizabeth A Morris Journal: J Magn Reson Imaging Date: 2017-11-02 Impact factor: 4.813
Authors: Samuel A Gold; Graham R Hale; Jonathan B Bloom; Clayton P Smith; Kareem N Rayn; Vladimir Valera; Bradford J Wood; Peter L Choyke; Baris Turkbey; Peter A Pinto Journal: World J Urol Date: 2018-05-21 Impact factor: 4.226
Authors: Simon Spohn; Chiara Jaegle; Thomas F Fassbender; Tanja Sprave; Eleni Gkika; Nils H Nicolay; Michael Bock; Juri Ruf; Matthias Benndorf; Christian Gratzke; Anca L Grosu; Constantinos Zamboglou Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-28 Impact factor: 9.236
Authors: Laura Evangelista; Fabio Zattoni; Gianluca Cassarino; Paolo Artioli; Diego Cecchin; Fabrizio Dal Moro; Pietro Zucchetta Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-08 Impact factor: 9.236
Authors: Felipe de Galiza Barbosa; Marcelo Araújo Queiroz; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Alberto Buchpiguel; Giovanni Guido Cerri Journal: Clinics (Sao Paulo) Date: 2018-09-21 Impact factor: 2.365